Statistical Design and Reporting of Randomised Controlled Trials for Raynaud’s Phenomenon
Author:
Publisher
Springer Nature Switzerland
Link
https://link.springer.com/content/pdf/10.1007/978-3-031-52581-0_16
Reference60 articles.
1. Senet P, Maillard H, Diot E, Lazareth I, Blaise S, Arnault JP, et al. Efficacy and safety of botulinum toxin in adults with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2023;75(3):459–67.
2. Yin H, Liu B, Li Q, Yan Q, Lu L. Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al. Arthritis Rheumatol. 2023;75(3):486.
3. Senn S. Seven myths of randomisation in clinical trials. Stat Med. 2013;32(9):1439–50.
4. Senet P, Vicaut E, collaborators B. Reply. Arthritis Rheumatol. 2023;75(3):486–7.
5. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3